Home›Trial›NCT07029581
🔬NCT07029581Phase 2RECRUITING

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Study Summary

Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

Conditions
Lewy Body Dementia Psychosis
Interventions / Drugs
ACP-204Placebo
View on ClinicalTrials.gov ↗
Sponsor
ACAD
ACADIA Pharmaceuticals
Neuroscience
D50/100
Study Details
Enrollment180 participants
Primary Completion—
Lead SponsorACADIA Pharmaceuticals Inc.
Data Retrieved2026-04-11 02:52:05.277036+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.